Ogilvie Syndrome Treatment Market: Is Neostigmine Emerging as the Gold Standard for Acute Colonic Pseudo-Obstruction?
Neostigmine's role in Ogilvie syndrome treatment — the acetylcholinesterase inhibitor achieving over 80% efficacy in colonic decompression for acute colonic pseudo-obstruction (ACPO) — represents the most clinically validated pharmacological intervention, with the Ogilvie Syndrome Treatment Market reflecting neostigmine-driven pharmacological treatment as the dominant commercial...
0 Commentarii 0 Distribuiri 5 Views